http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lee, Woochang,Oh, Byung-Keun,Kim, Yong-Wan,Choi, Jeong-Woo American Scientific Publishers 2006 Journal of Nanoscience and Nanotechnology Vol.6 No.11
<P>In the immunoassay based on surface plasmon resonance (SPR) system, the signal enhancement was done by means of the conjugate of gold (Au) nanoparticle-antibody fragment. Antibody fragment was prepared for the improved immobilization based on Au-thiol interaction. Through the ellipsometric analysis on surface, the conjugation between Au and antibody fragment was performed in the oriented manner. The optimal fabrication conditions such as concentration and incubation time were determined for the constant size of the fabricated nanoparticle-antibody conjugate. Through the plot of SPR angle difference versus antigen concentration, the linear correlation was achieved, of which the detection limit was 100 fg/ml.</P>
Fabrication of Protein A-Viologen Hetero Langmuir- Blodgett Film for Fluorescence Immunoassay
Lee, Woochang,Chun, Bum-Suk,Oh, Byung-Keun,Lee, Won-Hong,Park, Jeong-Woo The Korean Society for Biotechnology and Bioengine 2004 Biotechnology and Bioprocess Engineering Vol.9 No.4
Protein A molecular thin film was fabricated as a platform of antibody-based biosensor. For the immobilization of the protein A thin film, a viologen multilayer was built up using the Langmuir-Blodgett (LB) technique, and then, protein A was adsorbed on the viologen LB film by an electrostatic interaction force, which was formed as a hetero-film structure. For the deposition of viologen, surface pressure area ($\pi$-A) isotherm was investigated. The fabricated protein A-viologen hetero LB film was investigated using atomic force microscopy (AFM). Using the developed molecular film, antibody immobilization and fluorescence measurement was carried out.
Lee, Woochang,Oh, Byung-Keun,Choi, Jeong-Woo,Kim, Yong-Wan TaylorFrancis 2007 Molecular Crystals and Liquid Crystals Vol.463 No.1
<P> Protein A thin film was fabricated for antibody immobilization. Cysteine-terminated oligo-peptide composed of polar amino acids was utilized for the promotion of protein A immobilization induced by electrostatic interaction. The formation of the protein A film and the antibody immobilization was investigated with surface plasmon resonance (SPR) and atomic force microscopy, respectively. As the number of layer deposited on gold increased, the angle of plasmon resonance was increased accordingly. The fabricated antibody thin film was applied to the measurement of bovine serum albumin (BSA). The measured SPR angle was increased in proportion to the concentration of the applied BSA, of which the detection limit was 100 pM. These experimental results demonstrate that the developed synthetic peptide played an important role in the antibody immobilization for immunosensors.</P>
Lee Heerah,Kim Hyun-Ki,Yang Dong-Hoon,Hong Yong Sang,Lee Woochang,Lim Seok-Byung,Byeon Jeong-Sik,Chun Sail,Min Won-Ki 대한진단검사의학회 2021 Annals of Laboratory Medicine Vol.41 No.1
Dear Editor, Constitutional variants of the tumor suppressor gene adenomatous polyposis coli (APC) cause familial adenomatous polyposis (FAP), an autosomal dominant disorder characterized by numerous adenomatous colorectal polyps [1]. We detected a novel synonymous splice variant of APC in a family with FAP by next generation sequencing (NGS) and confirmed its impact on splicing by RNA sequencing.
Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays
Lee Jee Soo,Cho Eun Hye,Kim Boram,Hong Jinyoung,Kim Young-gon,Kim Yoonjung,Jang Ja-Hyun,Lee Seung-Tae,Kong Sun-Young,Lee Woochang,Shin Saeam,Song Eun Young 대한진단검사의학회 2024 Annals of Laboratory Medicine Vol.44 No.3
Circulating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an in-depth exploration of the clinical implementation of ctDNA assays. Notably, we examined existing evidence related to pre-analytical procedures, analytical components in current technologies, and result interpretation and reporting processes. The primary objective of this guidelines is to provide recommendations for the clinical utilization of ctDNA assays.